SAR445419 + fludarabine + cytarabine

SAR445419 + fludarabine + cytarabine is an investigational combination regimen for relapsed or refractory acute myeloid leukemia (AML). Patients first receive conditioning chemotherapy with fludarabine and cytarabine, followed by administration of SAR445419, an off-the-shelf, allogeneic, donor-derived natural killer (NK) cell therapy. The regimen aims to exploit chemotherapy-induced immune modulation followed by NK cell cytotoxicity for anti-leukemic effects. SAR445419 works primarily via immunologic cytotoxicity and NK cell replacement, targeting malignant cells in AML. This combination is being studied to determine dosing, safety, tolerability, and preliminary efficacy[1][2][3][4][7].